Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

Author:

Li Xintong1ORCID,Liu Yuanxin1,Gui Jun2,Gan Lu3,Xue Jianxin4ORCID

Affiliation:

1. Division of Thoracic Tumor Multimodality Treatment State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu 610041 China

2. State Key Laboratory of Systems Medicine for Cancer Renji‐Med X Clinical Stem Cell Research Center Ren Ji Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200127 China

3. Research Laboratory of Emergency Medicine Department of Emergency Medicine National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu 610041 China

4. Division of Thoracic Tumor Multimodality Treatment State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics Laboratory of Clinical Cell Therapy West China Hospital Sichuan University Chengdu 610041 China

Abstract

AbstractThe programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) axis inhibits T cell activity, impairing anti‐tumor immunity. Blocking this axis with therapeutic antibodies is one of the most promising anti‐tumor immunotherapies. It has long been recognized that PD‐1/PD‐L1 blockade reinvigorates exhausted T (TEX) cells already present in the tumor microenvironment (TME). However, recent advancements in high‐throughput gene sequencing and bioinformatic tools have provided researchers with a more granular and dynamic insight into PD‐1/PD‐L1 blockade‐responding cells, extending beyond the TME and TEX populations. This review provides an update on the cell identity, spatial distribution, and treatment‐induced spatiotemporal dynamics of PD‐1/PD‐L1 blockade responders. It also provides a synopsis of preliminary reports of potential PD‐1/PD‐L1 blockade responders other than T cells to depict a panoramic picture. Important questions to answer in further studies and the translational and clinical potential of the evolving understandings are also discussed.

Funder

National Natural Science Foundation of China

West China Hospital, Sichuan University

Science and Technology Department of Sichuan Province

Beijing Xisike Clinical Oncology Research Foundation

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3